)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Novakand Pharma
Novakand Pharma (NOVKAN) investor relations material
Novakand Pharma has been delisted
Novakand Pharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary28 Aug, 2026
Executive summary
Strategic shift from cardiovascular to orphan drug development for advanced ovarian cancer and leukemia, targeting patient groups lacking adequate treatments.
Nasdaq delisted the company in April 2026 after failed acquisition and lack of qualifying operations; new board and management appointed.
Focus on leveraging clinical results from the Kandova study and preparing for a pivotal clinical trial in 2028.
Financial highlights
Net sales remained at SEK 0.0 million (0.0) for H1 2026.
R&D expenses decreased sharply to SEK 2.5 million (15.8) year-over-year.
Operating loss improved to SEK -6.3 million (-19.5) compared to H1 2025.
Net loss after financial items was SEK -6.3 million (-19.2).
Cash flow from operations was SEK -7.1 million (-18.8); cash at period end SEK 9.0 million (27.6).
Outlook and guidance
Preparing for a rights issue in Q4 2026 to fund readiness for a pivotal clinical study starting in 2028.
Additional capital raise planned for 2027 to finance the clinical study through 2030.
Company expects current cash to cover basic operations until at least Q1 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Novakand Pharma
- Reverse acquisition of SVF Vaccines is pivotal amid reduced losses and risk of delisting.NOVKAN
Q4 2025 - Reverse takeover pursued after failed financing; SEK 18M asset write-down and cost cuts enacted.NOVKANQ3 2025
- Clinical milestones achieved, losses narrowed, but future activities hinge on new funding.NOVKANQ2 2025
- Strategic pivot to cardiovascular R&D, with strong cash position and high commercial potential.NOVKANQ3 2024
- Clinical milestones and improved financials position Kancera for continued development and partnerships.NOVKANQ2 2024
- Strategic shift to cardiovascular focus and Recardio partnership mark a pivotal quarter.NOVKANQ1 2025
- Strategic pivot to cardiovascular R&D and cost discipline position Kancera for next clinical phase.NOVKANQ4 2024
Next Novakand Pharma earnings date
H2 202619 Feb, 2027
Novakand Pharma
Next Novakand Pharma earnings date
H2 202619 Feb, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage